PGGM Investments Has $1.17 Million Position in Amgen Inc. (NASDAQ:AMGN)

PGGM Investments lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 56.4% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 4,102 shares of the medical research company’s stock after selling 5,315 shares during the period. PGGM Investments’ holdings in Amgen were worth $1,166,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Capital International Investors increased its stake in shares of Amgen by 547.8% during the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock worth $1,991,738,000 after purchasing an additional 5,923,915 shares during the period. Norges Bank bought a new stake in shares of Amgen in the fourth quarter valued at about $1,556,912,000. Vanguard Group Inc. grew its stake in shares of Amgen by 6.2% in the first quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock valued at $14,809,720,000 after acquiring an additional 3,045,657 shares in the last quarter. International Assets Investment Management LLC bought a new stake in Amgen in the 4th quarter valued at about $4,589,900,000. Finally, Janus Henderson Group PLC grew its position in shares of Amgen by 137.1% during the 1st quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company’s stock worth $676,984,000 after purchasing an additional 1,377,007 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Trading Down 0.5 %

AMGN stock traded down $1.54 during mid-day trading on Friday, reaching $333.99. The company’s stock had a trading volume of 2,106,216 shares, compared to its average volume of 1,890,833. Amgen Inc. has a 12 month low of $228.21 and a 12 month high of $346.85. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The business’s 50 day moving average price is $316.30 and its 200 day moving average price is $298.33. The company has a market cap of $179.16 billion, a price-to-earnings ratio of 47.71, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The company had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. Amgen’s quarterly revenue was up 22.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.98 EPS. On average, equities research analysts predict that Amgen Inc. will post 19.5 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.69%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Truist Financial reiterated a “buy” rating and issued a $320.00 price target on shares of Amgen in a research note on Friday, April 12th. William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Barclays raised Amgen from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $230.00 to $300.00 in a report on Friday, May 3rd. TD Cowen lowered their price target on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a report on Wednesday, April 17th. Finally, UBS Group raised their price objective on Amgen from $284.00 to $307.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $312.63.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.